Windham Venture Partners

@windhamvp

September 13, 2016

WellDoc® Announces Agreement with LifeScan Inc., a Johnson & Johnson Diabetes Care Company, to Finalize Commercial Partnership to Deliver Combined, Best-in-Class Digital Therapeutic Solution for Patients with Type 2 Diabetes

COLUMBIA, Md., (GLOBE NEWSWIRE) — Digital health technology leader WellDoc announced today it has entered a commercial partnership agreement withLifeScan Inc., one of the Johnson & Johnson Diabetes Care Companies (JJDCC) … Continued

September 12, 2016

Long-term Analysis of All 695 Patients Enrolled in Novocure’s Phase 3 Pivotal Trial in Newly Diagnosed Glioblastoma Confirms Superior Progression Free and Overall Survival Seen in the Trial’s Interim Analysis

Data demonstrate superior two, three and four year survival of patients treated with Optune™ together with temozolomide HELIER, JERSEY–(BUSINESS WIRE)– Novocure (NASDAQ:NVCR) announced today that long-term survival analysis of the … Continued

September 05, 2016

Holaira Hosts Educational Symposium on Targeted Lung Denervation (TLD) in Obstructive Lung Disease at ERS

COPD Patients Treated in First Sham Controlled Trial of Targeted Lung Denervation London– Holaira, Inc., a developer of medical devices to treat obstructive lung diseases, announced it will host an … Continued

Archives

© 2024 Windham Venture Partners 500 Fifth Avenue, Suite 3600, NY, NY 10110